Lipitor significantly reduced the average number of ischemic events by nearly 70 percent and total duration of events by more than 60 percent from baseline to week 18 of the study, and sustained these effects until the end of the trial at week 26. In 60 percent of the patients treated with Lipitor, all ischemic events were completely eliminated by the end of the study. This resulted in a substantial decrease in angina attacks and need for nitroglycerin treatment.

Lipitor significantly reduced the number of ischemic events and duration of angina attacks in patients with chronic stable angina, reducing angina attacks and the need for nitroglycerin treatment.

Paper

Lipitor provided an unexpectedly potent heart benefit in patients with chronic Stable Angina, according to new study

References

Citations